Kanilad

Lacosamide, the active ingredient in Kanilad, is a sodium channel blocker presented as an oral tablet for oral use. It is employed as adjunctive therapy for partial‑onset seizures in patients with epilepsy. GNH USA supplies Kanilad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is used in the management of epilepsy, specifically targeting focal seizure activity. - Partial‑onset seizures: reduces seizure frequency when added to existing antiepileptic regimens. - Focal seizures: provides additional seizure control as an adjunctive agent. - Adjunctive therapy in epilepsy: enhances overall seizure management when combined with other approved medications.

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness: transient sensation of light‑headedness or imbalance. - Nausea: mild to moderate stomach upset. - Fatigue: increased tiredness or lack of energy. - Headache: mild to moderate pain in the head region. - Blurred vision: temporary visual disturbances. - Diplopia: occasional double vision.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm requiring medical attention. - Suicidal ideation: emergence of thoughts of self‑harm. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: elevated liver enzymes or liver injury. - Respiratory depression: slowed breathing, especially with CNS depressants. - Anaphylactic reaction: rare but potentially life‑threatening allergic response.

When prescribing lacosamide, clinicians should consider several safety measures to minimize risk. - Monitor cardiac function: obtain baseline ECG and watch for PR‑interval changes. - Assess renal function: adjust dosing in patients with significant impairment. - Avoid abrupt discontinuation: taper gradually to prevent seizure worsening. - Use caution in hepatic impairment: monitor liver enzymes regularly. - Pregnancy: risk category unknown; discuss potential benefits and risks with the patient. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Lacosamide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole): may increase lacosamide plasma levels. - CYP3A4 inducers (e.g., rifampin): may reduce lacosamide exposure. - Other sodium channel blockers (e.g., carbamazepine): heightened risk of CNS depression.

Moderate Interactions (Monitor Closely): - Carbamazepine: may lower lacosamide concentrations, requiring dose adjustment. - Anticoagulants (e.g., warfarin): monitor INR for potential changes. - Alcohol: can enhance central nervous system effects, increasing dizziness or sedation.